Astellas Targets ¥4.3 Trillion Profit Push As Xtandi Pressure Builds

Astellas Pharma (ALPMY) is trying to give investors a new growth story as Xtandi, its blockbuster prostate cancer drug co-marketed with Pfizer (PFE), moves clos